Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Status:
Terminated
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive
disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5
mg daily or imatinib 800 mg daily. This study will find out the benefits and potential side
effects of taking sunitinib or imatinib for approximately one year.